Survival analysis of patients with advanced non‐small cell lung cancer receiving tyrosine kinase inhibitor (TKI) treatment: A multi‐center retrospective study

Publisher： John Wiley & Sons Inc

E-ISSN： 1759-7714|9|2|278-283

ISSN： 1759-7706

Source： Thoracic Cancer, Vol.9, Iss.2, 2018-02, pp. : 278-283

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Histological transformation from non‐small cell to small cell lung carcinoma after treatment with epidermal growth factor receptor‐tyrosine kinase inhibitor

By  

Thoracic Cancer, Vol. 6, Iss. 6, 2015-11 ,pp. : 800-804

John Wiley & Sons Inc

Access to resources Recommend Favorite

Treatment and prognostic analysis of patients with leptomeningeal metastases from non‐small cell lung cancer

By  

Thoracic Cancer, Vol. 6, Iss. 4, 2015-07 ,pp. : 407-412

John Wiley & Sons Inc

Access to resources Recommend Favorite

Interleukin polymorphisms associated with overall survival, disease‐free survival, and recurrence in non‐small cell lung cancer patients

By  

Molecular Carcinogenesis, Vol. 54, Iss. S1, 2015-06 ,pp. : E172-E184

John Wiley & Sons Inc

Access to resources Recommend Favorite

Basic fibroblast growth factor shows prognostic impact on survival in operable non‐small cell lung cancer patients

By  

Thoracic Cancer, Vol. 6, Iss. 4, 2015-07 ,pp. : 450-457

John Wiley & Sons Inc

Access to resources Recommend Favorite

Subsequent treatment of epidermal growth factor receptor‐tyrosine kinase inhibitor failure in patients with advanced lung adenocarcinoma

By  

Thoracic Cancer, Vol. 6, Iss. 6, 2015-11 ,pp. : 678-686

John Wiley & Sons Inc

Access to resources Recommend Favorite